Author(s):
Smit J. Patel, Bindiya Chauhan, Basheer Shaikh, Priyanka Chavan, Nadeem Khan
Email(s):
patelsmit87@gmail.com , chauhanbindiya@yahoo.co.in
DOI:
10.52711/0974-360X.2024.00771
Address:
Smit J. Patel1,2, Bindiya Chauhan2,3*, Basheer Shaikh4, Priyanka Chavan4, Nadeem Khan4
1Department of Quality Assurance, Jai Research Foundation, Valsad, Gujarat, India.
2Department of Quality Assurance, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, India.
3Department of Quality Assurance, SGT College of Pharmacy, SGT University, Gurugram, Haryana, India.
4Department of Chemistry, Jai Research Foundation, Valsad, Gujarat, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 10,
Year - 2024
ABSTRACT:
Remogliflozin is an inhibitor of sodium-glucose cotransporter 2 inhibitors (SGLT-2) protein and plays an important role in the treatment and management of type-2 diabetes mellitus. In this study, a selective isocratic method was developed and validated using liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for the determination of remogliflozin in rat plasma. Acetonitrile with formic acid was used as a precipitating agent. Chromatographic separation was achieved by using X select CSH Fluorophenyl (150 mm x 4.6 mm, 3.5 µm) column and 0.1% formic acid in milli-Q water (20%) and acetonitrile (80%), v/v as a mobile phase for isocratic elution method. Flow rate and injection volume were maintained at 0.7 mL/min and 10 µL, respectively. The validated method was linear in the range of 15– 2009 ng/mL with the lower limit of quantification (LLOQ) of 18 ng/mL. Also, the method was precise with a % CV less than 5.75 and accuracy within ±10% of nominal concentration. The method is accurate, simple, precise, and suitable for its application in further bioequivalence and pharmacokinetic studies.
Cite this article:
Smit J. Patel, Bindiya Chauhan, Basheer Shaikh, Priyanka Chavan, Nadeem Khan. Development and Validation of Selective and Sensitive Liquid Chromatography - Tandem Mass Spectroscopy (UHPLC-MS/MS) Method for Bioanalysis of Remogliflozin in Rat Plasma. Research Journal of Pharmacy and Technology. 2024; 17(10):5016-2. doi: 10.52711/0974-360X.2024.00771
Cite(Electronic):
Smit J. Patel, Bindiya Chauhan, Basheer Shaikh, Priyanka Chavan, Nadeem Khan. Development and Validation of Selective and Sensitive Liquid Chromatography - Tandem Mass Spectroscopy (UHPLC-MS/MS) Method for Bioanalysis of Remogliflozin in Rat Plasma. Research Journal of Pharmacy and Technology. 2024; 17(10):5016-2. doi: 10.52711/0974-360X.2024.00771 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-10-56
8.0 REFERENCES:
1. American Diabetes Association, 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41: S73-S85.
2. Wright EM, and Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch: European Journal of Physiology. Feb 2004; 447: 510–18. doi: 10.1007/s00424-003-1063-6.
3. Atal S, Zeenat F, Singh S, et al. Remogliflozin: the new low cost SGLT-2 inhibitors for type 2 diabetes mellitus. Diabetology International. Oct 2020; 12(3): 247-53. doi: 10.1007/s13340-020-00472-4.
4. Madaan T, Akhtar M, Najmi AK. Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. Oct 2016; 93: 244-52. doi: 10.1016/j.ejps.2016.08.025
5. Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Advance in Experimental Medicine and Biology. 2021; 1307: 213-30. doi: 10.1007/5584_2020_479
6. Markham A. Remogliflozin etabonate: first global approval. Drugs. Jul 2019; 79(10): 1157-61. doi:10.1007/s40265-019-01150-9.
7. Sathiyaraj M, Vijay Amirtharaj R, Senthilkumar N. Bioanalytical method development and validation of esomeprazole in human plasma by LCMS/MS. Asian Journal of Research in Chemistry. Apr 2010; 3(2): 477-484.
8. Anil Kumar Meher, Anandan P, Mukhopadhyay M. Estimation of Isradipine in human plasma by LCMS/MS. Asian Journal of Research in Chemistry. May 2011; 4(5): 750-753.
9. Chauhan B, Jalalpure S. Analysis of amikacin in human serum by UHPLC With fluorescence detector Using chloro-formate reagent with glycine. Pharmaceutical Methods. 2016; 7(2): 99-103. doi:10.5530/phm.2016.7.15
10. Reddy S, Nayak N, Ahmed I, et al. Development and validation of two LCMS/MS methods for simultaneous estimation of oseltamivir and its metabolite in human plasma and application in bioequivalence study. Asian Journal of Pharmaceutical Analysis. 2016; 6(2): 91-101. doi: 10.5958/2231-5675.2016.00014.4
11. Saudagar R.B, Thete P. Bioanalytical method validation: A concise review. Asian Journal of Research in Pharmaceutical Sciences. 2018; 8(2):107-114. doi: 10.5958/2231-5659.2018.00019.X
12. Jumde H, Mankar S. Review on development of analytical method and validation by reverse phase – high performance liquid chromatography. Asian Journal of Pharmacy and Technology. 2022; 12(2): 179-2. doi: 10.52711/2231-5713.2022.00030
13. Ghagare P, Patil A, Deshmane B, et al. Review on pharmaceutical validation. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(1): 17-26. doi: 10.5958/0975-4377.2020.00004.X
14. Shingote V, Mankar S, Dighe S. A review article on analytical methods development and validation. Research Journal of Science and Technology. 2022; 14(1): 77-3. doi: 10.52711/2349-2988.2022.00012
15. Raghavendra Babu N, Padmavathi Y, Priyanka S, et al. Development of sensitive spectrophotometric method for analysis of darifenacin hydrobromide liposomes in rat plasma. Asian Journal of Pharmaceutical Analysis. 2017; 7(1): 41-47. doi: 10.5958/2231-5675.2017.00008.4
16. Kumar P, Chaudhary M, Bhattacharya S, et al. Validated analytical method development of celecoxib in bulk, tablet and rat plasma by UV-Spectroscopy. Research Journal of Pharmacy and Technology. Jul 2010; 3(3): 894-896.
17. Karanam S, Reena Jyothi Swarupa V. Stability indicating analytical method development and validation for simultaneous estimation of valsartan and hydrochlorothiazide in tablet dosage form. Asian Journal of Pharmaceutical Analysis. Jan 2016; 6(1): 7-14. doi: 10.5958/2231-5675.2016.00002.8
18. Itigimatha N, Chadchan KS, et al. Simple and sensitive RP-HPLC and UV spectroscopic methods for the determination of remogliflozin etabonate in pure and pharmaceutical formulations. Turkish Journal of Pharmaceutical Sciences. Apr 2022; 19(2): 213-19. doi:10.4274/tjps.galenos.2021.55381.
19. Shah DA, Gondalia II, et al. Stability indicating liquid chromatographic method for estimation of remogliflozin etabonate. Journal of Chemical Metrology. 2020; 14: 125-32.
20. Attimarad M, Nair AB, et al. Development and validation of green UV derivative spectrophotometric methods for simultaneous determination metformin and remogliflozin from formulation: evaluation of greenness. International Journal of Environmental Research and Public Health. Jan 2021; 18(2): 448. doi:10.3390/ijerph18020448.
21. Shah DA, Gondalia II, et al. Stability indicating thin-layer chromatographic method for estimation of antidiabetic drug remogliflozin etabonate. Future Journal of Pharmaceutical Sciences. 2021; 7(1): 83 doi: https://doi.org/10.1186/s43094-021-00230-6
22. Sigafoos JF, Bowers GD, et al. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug metabolism and Disposition: The Biological Fate of Chemicals. Nov. 2012; 40(11): 2090-101. doi:10.1124/dmd.112.047258.
23. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (last time accessed: October 16, 2023)
24. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf (last time accessed: October 18, 2023)